AngioDynamics ANGO Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1.
The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about AngioDynamics's noncash or part noncash acquisition net nonmonetary assets acquired liabilities assumed1.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AngioDynamics's noncash or part noncash acquisition net nonmonetary assets acquired liabilities assumed1?
- AngioDynamics (ANGO) reported noncash or part noncash acquisition net nonmonetary assets acquired liabilities assumed1 of -$445K in Q4 2025.
- How has AngioDynamics's noncash or part noncash acquisition net nonmonetary assets acquired liabilities assumed1 changed year-over-year?
- AngioDynamics's noncash or part noncash acquisition net nonmonetary assets acquired liabilities assumed1 decreased by 10.1% year-over-year, from -$404K to -$445K.
- What is the long-term trend for AngioDynamics's noncash or part noncash acquisition net nonmonetary assets acquired liabilities assumed1?
- Over 2 years (2021 to 2025), AngioDynamics's noncash or part noncash acquisition net nonmonetary assets acquired liabilities assumed1 has grown at a -40.6% compound annual growth rate (CAGR), from -$139K to -$49K.
- What does noncash or part noncash acquisition net nonmonetary assets acquired liabilities assumed1 mean?
- This represents the value of assets acquired or liabilities assumed in business combinations that were settled through means other than cash, such as stock issuance. It provides transparency into the total consideration paid for acquisitions beyond the cash flow statement. This is essential for understanding the true cost and financing structure of inorganic growth strategies.